News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onyx Pharmaceuticals, Inc. (ONXX) Snubbing Amgen (AMGN) Paves Way for 89% Premium; Pfizer Inc. (PFE), Novartis AG (NVS) Throw Names Into Hat


7/2/2013 6:52:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Onyx Pharmaceuticals has rejected Amgen's takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset—the blood cancer drug Kyprolis.

Help employers find you! Check out all the jobs and post your resume.

Read at NBC
Read at The Street.com
Read at Reuters

comments powered by Disqus
NBC
The Street.com
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES